Cargando…

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

BACKGROUND: This study aimed to determine whether single nucleotide polymorphisms (SNPs) in genes involved in DNA repair or metabolism of taxanes or platinum could predict toxicity or response to first-line chemotherapy in ovarian cancer. METHODS: Twenty-six selected SNPs in 18 genes were genotyped...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambrechts, Sandrina, Lambrechts, Diether, Despierre, Evelyn, Van Nieuwenhuysen, Els, Smeets, Dominiek, Debruyne, Philip R, Renard, Vincent, Vroman, Philippe, Luyten, Daisy, Neven, Patrick, Amant, Frédéric, Leunen, Karin, Vergote, Ignace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359565/
https://www.ncbi.nlm.nih.gov/pubmed/25881102
http://dx.doi.org/10.1186/s40360-015-0001-5
_version_ 1782361433157140480
author Lambrechts, Sandrina
Lambrechts, Diether
Despierre, Evelyn
Van Nieuwenhuysen, Els
Smeets, Dominiek
Debruyne, Philip R
Renard, Vincent
Vroman, Philippe
Luyten, Daisy
Neven, Patrick
Amant, Frédéric
Leunen, Karin
Vergote, Ignace
author_facet Lambrechts, Sandrina
Lambrechts, Diether
Despierre, Evelyn
Van Nieuwenhuysen, Els
Smeets, Dominiek
Debruyne, Philip R
Renard, Vincent
Vroman, Philippe
Luyten, Daisy
Neven, Patrick
Amant, Frédéric
Leunen, Karin
Vergote, Ignace
author_sort Lambrechts, Sandrina
collection PubMed
description BACKGROUND: This study aimed to determine whether single nucleotide polymorphisms (SNPs) in genes involved in DNA repair or metabolism of taxanes or platinum could predict toxicity or response to first-line chemotherapy in ovarian cancer. METHODS: Twenty-six selected SNPs in 18 genes were genotyped in 322 patients treated with first-line paclitaxel-carboplatin or carboplatin mono-therapy. Genotypes were correlated with toxicity events (anemia, neutropenia, thrombocytopenia, febrile neutropenia, neurotoxicity), use of growth factors and survival. RESULTS: The risk of anemia was increased for variant alleles of rs1128503 (ABCB1, C > T; p = 0.023, OR = 1.71, 95% CI = 1.07-2.71), rs363717 (ABCA1, A > G; p = 0.002, OR = 2.08, 95% CI = 1.32-3.27) and rs11615 (ERCC1, T > C; p = 0.031, OR = 1.61, 95% CI = 1.04-2.50), while it was decreased for variant alleles of rs12762549 (ABCC2, C > G; p = 0.004, OR = 0.51, 95% CI = 0.33-0.81). Likewise, increased risk of thrombocytopenia was associated with rs4986910 (CYP3A4, T > C; p = 0.025, OR = 4.99, 95% CI = 1.22-20.31). No significant correlations were found for neurotoxicity. Variant alleles of rs2073337 (ABCC2, A > G; p = 0.039, OR = 0.60, 95% CI = 0.37-0.98), rs1695 (ABCC1, A > G; p = 0.017, OR = 0.55, 95% CI 0.33-0.90) and rs1799793 (ERCC2, G > A; p = 0.042, OR = 0.63, 95% CI 0.41-0.98) associated with the use of colony stimulating factors (CSF), while rs2074087 (ABCC1, G > C; p = 0.011, OR = 2.09, 95% CI 1.18-3.68) correlated with use of erythropoiesis stimulating agents (ESAs). Homozygous carriers of the rs1799793 (ERCC2, G > A) G-allele had a prolonged platinum-free interval (p = 0.016). CONCLUSIONS: Our data reveal significant correlations between genetic variants of transport, hepatic metabolism, platinum related detoxification or DNA damage repair and toxicity or outcome in ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0001-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4359565
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43595652015-03-15 Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer Lambrechts, Sandrina Lambrechts, Diether Despierre, Evelyn Van Nieuwenhuysen, Els Smeets, Dominiek Debruyne, Philip R Renard, Vincent Vroman, Philippe Luyten, Daisy Neven, Patrick Amant, Frédéric Leunen, Karin Vergote, Ignace BMC Pharmacol Toxicol Research Article BACKGROUND: This study aimed to determine whether single nucleotide polymorphisms (SNPs) in genes involved in DNA repair or metabolism of taxanes or platinum could predict toxicity or response to first-line chemotherapy in ovarian cancer. METHODS: Twenty-six selected SNPs in 18 genes were genotyped in 322 patients treated with first-line paclitaxel-carboplatin or carboplatin mono-therapy. Genotypes were correlated with toxicity events (anemia, neutropenia, thrombocytopenia, febrile neutropenia, neurotoxicity), use of growth factors and survival. RESULTS: The risk of anemia was increased for variant alleles of rs1128503 (ABCB1, C > T; p = 0.023, OR = 1.71, 95% CI = 1.07-2.71), rs363717 (ABCA1, A > G; p = 0.002, OR = 2.08, 95% CI = 1.32-3.27) and rs11615 (ERCC1, T > C; p = 0.031, OR = 1.61, 95% CI = 1.04-2.50), while it was decreased for variant alleles of rs12762549 (ABCC2, C > G; p = 0.004, OR = 0.51, 95% CI = 0.33-0.81). Likewise, increased risk of thrombocytopenia was associated with rs4986910 (CYP3A4, T > C; p = 0.025, OR = 4.99, 95% CI = 1.22-20.31). No significant correlations were found for neurotoxicity. Variant alleles of rs2073337 (ABCC2, A > G; p = 0.039, OR = 0.60, 95% CI = 0.37-0.98), rs1695 (ABCC1, A > G; p = 0.017, OR = 0.55, 95% CI 0.33-0.90) and rs1799793 (ERCC2, G > A; p = 0.042, OR = 0.63, 95% CI 0.41-0.98) associated with the use of colony stimulating factors (CSF), while rs2074087 (ABCC1, G > C; p = 0.011, OR = 2.09, 95% CI 1.18-3.68) correlated with use of erythropoiesis stimulating agents (ESAs). Homozygous carriers of the rs1799793 (ERCC2, G > A) G-allele had a prolonged platinum-free interval (p = 0.016). CONCLUSIONS: Our data reveal significant correlations between genetic variants of transport, hepatic metabolism, platinum related detoxification or DNA damage repair and toxicity or outcome in ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0001-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-27 /pmc/articles/PMC4359565/ /pubmed/25881102 http://dx.doi.org/10.1186/s40360-015-0001-5 Text en © Lambrechts et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lambrechts, Sandrina
Lambrechts, Diether
Despierre, Evelyn
Van Nieuwenhuysen, Els
Smeets, Dominiek
Debruyne, Philip R
Renard, Vincent
Vroman, Philippe
Luyten, Daisy
Neven, Patrick
Amant, Frédéric
Leunen, Karin
Vergote, Ignace
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
title Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
title_full Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
title_fullStr Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
title_full_unstemmed Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
title_short Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
title_sort genetic variability in drug transport, metabolism or dna repair affecting toxicity of chemotherapy in ovarian cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359565/
https://www.ncbi.nlm.nih.gov/pubmed/25881102
http://dx.doi.org/10.1186/s40360-015-0001-5
work_keys_str_mv AT lambrechtssandrina geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT lambrechtsdiether geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT despierreevelyn geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT vannieuwenhuysenels geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT smeetsdominiek geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT debruynephilipr geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT renardvincent geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT vromanphilippe geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT luytendaisy geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT nevenpatrick geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT amantfrederic geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT leunenkarin geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT vergoteignace geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer
AT geneticvariabilityindrugtransportmetabolismordnarepairaffectingtoxicityofchemotherapyinovariancancer